These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11521772)

  • 61. Efficacy of intensive phonatory-respiratory treatment (LSVT) for presbyphonia: two case reports.
    Lu FL; Presley S; Lammers B
    J Voice; 2013 Nov; 27(6):786.e11-23. PubMed ID: 24119640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical approach to monitoring variability associated with adductor spasmodic dysphonia.
    Yeung JC; Fung K; Bornbaum CC; Day AM; Dzioba A; Parsa V; Levee T; Doyle PC
    J Otolaryngol Head Neck Surg; 2011 Aug; 40(4):343-9. PubMed ID: 21777554
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Personality and voice disorders: a superfactor trait analysis.
    Roy N; Bless DM; Heisey D
    J Speech Lang Hear Res; 2000 Jun; 43(3):749-68. PubMed ID: 10877443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Everyday listeners' impressions of speech produced by individuals with adductor spasmodic dysphonia.
    Nagle KF; Eadie TL; Yorkston KM
    J Commun Disord; 2015; 58():1-13. PubMed ID: 26209746
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
    Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
    Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Perceptual analyses of spasmodic dysphonia before and after treatment.
    Cannito MP; Woodson GE; Murry T; Bender B
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia.
    Ford CN; Bless DM; Lowery JD
    Otolaryngol Head Neck Surg; 1990 Nov; 103(5 ( Pt 1)):752-8. PubMed ID: 2126097
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.
    Watts C; Nye C; Whurr R
    Clin Rehabil; 2006 Feb; 20(2):112-22. PubMed ID: 16541931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Symptom improvement of spastic dysphonia in response to phonatory tasks.
    Bloch CS; Hirano M; Gould WJ
    Ann Otol Rhinol Laryngol; 1985; 94(1 Pt 1):51-4. PubMed ID: 3970505
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inferring speaker attributes in adductor spasmodic dysphonia: ratings from unfamiliar listeners.
    Isetti D; Xuereb L; Eadie TL
    Am J Speech Lang Pathol; 2014 May; 23(2):134-45. PubMed ID: 24686338
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Teaching video NeuroImage: Spasmodic dysphonia: adductor and abductor.
    Reich SG; Meyer T
    Neurology; 2008 May; 70(19):e78. PubMed ID: 18458222
    [No Abstract]   [Full Text] [Related]  

  • 73. Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report.
    Koufman JA; Rees CJ; Halum SL; Blalock D
    Ann Otol Rhinol Laryngol; 2006 Feb; 115(2):97-102. PubMed ID: 16514790
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Kodama N; Minoda R; Kumai Y
    Auris Nasus Larynx; 2014 Jun; 41(3):285-9. PubMed ID: 24369905
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Spectral amplitude measures of adductor spasmodic dysphonic speech.
    Cannito MP; Buder EH; Chorna LB
    J Voice; 2005 Sep; 19(3):391-410. PubMed ID: 16102666
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Judgment of voice improvement after recurrent laryngeal nerve section for spastic dysphonia: clinicians versus patients.
    Sapir S; Aronson AE; Thomas JE
    Ann Otol Rhinol Laryngol; 1986; 95(2 Pt 1):137-41. PubMed ID: 3516048
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Abnormal adductor movement of the vocal cords in spasmodic dysphonia].
    Shibusawa M
    Nihon Jibiinkoka Gakkai Kaiho; 1993 Apr; 96(4):659-64. PubMed ID: 8509938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.